20 results about "Soft tissue infection" patented technology

The invention relates to tedizolid gel and a preparation method thereof. The tedizolid gel is prepared from the following raw materials and auxiliary materials: an active component, a gel matrix, an alcohol solvent, a bacteriostatic agent, a pH regulator and water, the active component is tedizolid or ester thereof, or pharmaceutically acceptable salt thereof; the gel matrix is carbomer. The tedizolid gel can increase the local tissue free drug concentration of the skin of the bacterial infection part of an organism through transdermal absorption, so that the bacteriostatic activity of the tedizolid gel is better played, the treatment effect on local acute bacterial skin and skin soft tissue infection is improved, and the adverse reaction is reduced.

The present application relates to the field of traditional Chinese medicine, and particularly provides a traditional Chinese medicine composition for treating skin redness, swelling, heat and pain, and a preparation method thereof. The composition is composed of two components, A and B. The component A contains isatis root, cortex lycii, pueraria, gardenia, sophora flavescens and giant knotweed. The component B contains radix trichosanthis, phellodendri, curcuma, rhubarb, radix angelicae dahuricae, magnolia officinalis, pericarpium citri reticulatae, atractylodes and licorice. The component A is decocted to obtain juice, and the component B is ground into powder and mixed uniformly. When used, a certain amount of the component A is mixed with a certain amount of the component B to form a paste, which is wrapped with single-layer gauze and applied to the pain site. After 1 hour, the paste is removed. The composition has the effects of clearing heat and resolving toxins, cooling blood and drying dampness, removing blood stasis and activating collaterals, and relieving swelling and pain. The combined use of the drugs has a remarkable effect on skin soft tissue redness, swelling, heat and pain caused by gout, skin soft tissue infection, fracture and sprain.

The invention relates to a biomarker combination for diagnosis of immune depletion type bone and soft tissue infection and application of the biomarker combination, the biomarker combination is cystatin C and granzyme K, when cystatin Cgt; when the concentration is 0.15 mg / L and the grazyme K is 30-70 pg / mL, or when the Cst3 + Arg-1 + macrophages account for the total quantity gt of the macrophages; when the content of the Gzmk is 15% and the content of the Gzmk + Tigit + CD8 + T cells accounts for 10-35% of the content of the CD8 + T cells, the bone and soft tissue infection immune microenvironment of the subject is in a depleted state. Compared with the prior art, the built biomarker combination exceeds a traditional binary diagnosis mode for judging whether infection exists or not, and whether the bone and soft tissue infection local immune microenvironment is in a depletion state or not can be accurately evaluated.

The utility model discloses flexible plasma equipment for treating skin soft tissue infection, and particularly relates to the field of flexible plasma equipment. Comprising a polyimide film, a plurality of electrodes are distributed on the polyimide film in an array mode, all the electrodes are connected with a power source in parallel through electric wires, a rubber plate adheres to one side of the polyimide film, and a plurality of connecting holes are formed in the upper side and the lower side of the rubber plate. The upper side and the lower side of the upper end of the rubber plate are rotationally connected with connecting blocks, the connecting blocks are in threaded connection with limiting bolts, and the limiting bolts are matched with the connecting holes. By adopting the technical scheme of the utility model, the problems of drug resistance and increased treatment difficulty caused by the fact that the existing skin soft tissue infection is mainly treated by antibiotics are solved, and the treatment effect of the skin soft tissue infection is improved.

The invention discloses a preparation method of a micro-needle mediated two-channel electrochemical aptamer sensor, which comprises the following steps: firstly, constructing an interstitial fluid extraction module based on a hollow micro-needle, the interstitial fluid extraction module comprising a substrate and a hollow micro-needle array arranged on the substrate; a flower-like gold nanostructure is deposited on the surface of DSPCE to obtain a DSPCE-Au electrode, a vancomycin aptamer marked by electrochemical signal molecules and a C-reactive protein aptamer / auxiliary probe hybrid double strand are connected to the DSPCE-Au electrode through Au-S bonds to obtain an electrochemical detection module, and the electrochemical detection module is integrated with a mesenchymal fluid extraction module. The sensor can be used for diagnosis and treatment monitoring of necrotic soft tissue infection by virtue of the painless transdermal sampling capability of the microneedle, the high-specificity recognition characteristic of the aptamer and the high-sensitivity detection advantage of the electrochemical sensor, and has the advantages of minimally invasive property, portability, continuous monitoring, real-time data acquisition and the like; the problems that an existing detection method is long in consumed time, painful, complex in equipment and the like are solved.

The invention discloses application of Spp1 in auxiliary diagnosis, treatment or prognosis of bone and soft tissue infection caused by staphylococcus aureus. The Spp1 comprises an Spp1 gene, mRNA expressed by the Spp1 gene or an Spp1 protein expressed by the Spp1 gene, can be used for preparing a reagent / kit for auxiliary diagnosis, treatment or prognosis of the bone and soft tissue infection caused by the staphylococcus aureus and can also be used for preparing and screening drugs for treating the bone and soft tissue infection caused by the staphylococcus aureus, and the nucleotide sequence of the Spp1 gene is shown as NCBI Reference Sequence: NC000071.7. Based on a multi-omics database and a gene editing technology, the bone and soft tissue infection molecule subtype and the key target Spp1 are found, theoretical support is provided for development of diagnostic markers and therapeutic drugs, and the method has definite clinical transformation and industrialization prospects.

The application discloses a synergistic bactericidal composition, comprising the following components: a toona sinensis extract: 16-2048 mu g / mL; a macrolide antibiotic: 0.0625-4096 mu g / mL; the bacteria are staphylococcus aureus or methicillin-resistant staphylococcus aureus, and the macrolide antibiotic is erythromycin or azithromycin. The application further discloses a use of the synergistic bactericidal composition in preparation of a medicine for treating skin and soft tissue infections. The composition provided by the application can convert the traditional macrolide antibiotics such as erythromycin and azithromycin which only have a bacteriostatic effect into a preparation which has clear bactericidal activity on staphylococcus aureus and drug-resistant strains thereof. After the toona sinensis extract is combined with the antibiotic, a synergistic effect is exhibited, and the concentration of the toona sinensis extract and the antibiotic required when the toona sinensis extract and the antibiotic are used alone can be greatly reduced.

The invention discloses application of alpha-hederin in preparation of a medicine for preventing or treating staphylococcus aureus infectious diseases, and belongs to the technical field of medicines. The staphylococcus aureus infectious disease is one of skin or soft tissue infection, pneumonia, osteoarthritis, mastitis, enteritis, endocarditis, urinary tract infection and enteritis. The medicine does not have an in-vitro direct sterilization function on sensitive and methicillin-resistant staphylococcus aureus, but can remarkably promote infected cells to remove thalli under a cell infection condition, so that the medicine plays a role in resisting sensitive and methicillin-resistant staphylococcus aureus infection by improving the anti-infection immune level of the cells.

The invention provides application of bacteroides fragilis and / or an extract capsular polysaccharide A thereof in preparation of a composition for improving and / or treating skin and soft tissue infection. Different animal skin and soft tissue infection model tests prove that viable bacteria, lysate, inactivated bacteria and zwitter-ion capsular polysaccharide A of Bacteroides fragilis ZY-312 with the preservation number of CGMCC No.10685 have the effects of improving and treating skin and soft tissue infection. The inactivated bacteroides fragilis powder has a good effect of improving skin and soft tissue infection under formulas with different concentrations, does not have side effects on organisms, has very good edible and application prospects, and is a good product which is suitable for human body to eat and is used for health care and improving skin and soft tissue infection.

Cloxacillin Sodium is an organic compound with the molecular formula C 19 H 18 Cl2N3NaO6S. It is a white powder or crystalline powder; slightly smelly and bitter; hygroscopic. Cloxacillin sodium is prepared into an injection for administration, which is mainly used to treat penicillinase-producing Staphylococcus aureus infections, including sepsis, endocarditis, pneumonia, and skin and soft tissue infections. Because it has multiple easily hydrolyzed groups, such as β-lactam rings and amide bonds, it has poor stability and is easily hydrolyzed. In order to improve the stability of cloxacillin sodium, the present invention uses Bicine (N,N-bis(hydroxyethyl)glycine) as a buffer salt and CMC / AA / AM as a hygroscopic agent (carboxymethyl cellulose (CMC) connected to acrylic acid (AA) connected to acrylamide (AM)), and adopts a sterile packaging process to obtain a highly stable cloxacillin sodium preparation.

The invention belongs to the technical field of clinical examination and diagnosis, and relates to a molecular marker for diagnosing necrotic soft tissue infection as well as application and a model of the molecular marker. The molecular marker is selected from one or a combination of more of estrone sulfate, 3-hydroxydecanoic acid and N-lactoyl-phenylalanine. The molecular marker, the application and the construction method can be quickly, simply, sensitively and specifically used for early diagnosis of necrotic soft tissue infection.

The invention discloses novel fusidic acid crystal forms as well as a preparation method and application thereof. The novel fusidic acid crystal forms are NY01 and NY02. The fusidic acid new crystal form NY01 or NY02 provided by the invention can be prepared into preparation forms such as capsules, tablets, emulsifiable paste, gel and the like with other pharmaceutically acceptable auxiliary materials so as to adapt to different administration routes; the pharmaceutical composition is used for treating osteomyelitis, septicemia, endocarditis, pneumonia, cystic fibrosis, skin and soft tissue infection, surgical operation infection or trauma infection caused by sensitive microorganisms, especially staphylococcus.

The invention discloses an application of cefmenoxime hydrochloride in preparing a medicine for treating diseases caused by mycobacterium tuberculosis infection and / or non-tuberculous mycobacterium infection, and belongs to the technical field of biomedicine. The invention provides an application of cefmenoxime hydrochloride in preparing a medicine for treating diseases caused by mycobacterium tuberculosis infection and / or non-tuberculous mycobacterium infection. The mycobacterium tuberculosis includes at least one of H37Rv, H37Ra and BCG, and the non-tuberculous mycobacteria includes mycobacterium abscessus. The invention finds that the medicine exerts an antibacterial effect by inhibiting the synthesis of bacterial cell walls and affecting the synthesis of bacterial proteins. The medicine can effectively inhibit tuberculosis caused by mycobacterium tuberculosis infection and lung infection, skin and soft tissue infection, lymphadenitis and other diseases caused by non-tuberculous mycobacterium infection. Therefore, cefmenoxime hydrochloride can be used as a novel anti-tuberculosis medicine with high efficiency and low toxicity.

The utility model belongs to the field of medical instruments, and particularly relates to a skin soft tissue infection disc type flushing and drainage device which comprises a protection disc, a mounting hole is formed in the center of the top of the protection disc, a protection plug is clamped in the mounting hole, at least two limiting holes are formed in the top of the protection plug, and the limiting holes are communicated with the protection plug. A flushing pipe and a drainage pipe are installed in the two limiting holes respectively, and the top end of the flushing pipe is connected with a flushing bag. Through mutual cooperation of the protection disc, the bottom disc, the flushing pipe, the drainage pipe and other structures, an infection source can be effectively flushed, meanwhile, damage to wounds of a patient caused by negative pressure drainage is avoided, and compared with a traditional VSD seepage suction mode, it is avoided that due to thick seepage blockage, clinical doctors change dressings at high frequency, and the operation efficiency is improved. The drainage device is simple in structure and convenient to use, labor cost is saved, the sealing performance between the protection disc and the bottom disc can be enhanced through mutual cooperation of the protection disc, the bottom disc and the sealing groove, and leakage of wound seepage and flushing dirty liquid in the flushing drainage process is avoided.

The invention relates to a joint infection bimodal flexible monitoring sensor based on hydrogel and a preparation method thereof. The sensor comprises a flexible film substrate layer, a packaging layer, a PEDOT: PSS-PVA hydrogel pressure module and an NTC thermistor temperature module, and the PEDOT: PSS-PVA hydrogel pressure module and the NTC thermistor temperature module share a negative electrode. The preparation method comprises the following steps: preparing hydrogel ink, carrying out cross-linking bath, forming a hydrogel structure through low-temperature cross-linking 3D printing, preparing a PDMS film, carrying out plasma surface treatment on the hydrogel and the PDMS film, printing a circuit and a temperature sensing element, and finally assembling the sensor. Compared with the prior art, the sensor has the advantages of high sensitivity, wide measurement range and high stability, can accurately and synchronously acquire temperature and pressure signals of a joint part, realizes real-time monitoring and early warning of bone and soft tissue infection, breaks through the limitation of traditional diagnosis, and improves the early diagnosis efficiency and treatment compliance.

The application belongs to the technical field of biological medicine, and provides application of ferulic acid in preparation of a photolysis inhibitor of tigecycline and minocycline. The ferulic acid can significantly inhibit degradation of tigecycline or minocycline under light conditions, and further enhance the antibacterial activity of tigecycline or minocycline under light conditions. Compared with the treatment of tigecycline alone, the addition of ferulic acid can significantly enhance the treatment effect of tigecycline or minocycline as an external medicine on skin or soft tissue infection, effectively expand the drug dosage form of tigecycline or minocycline, and provide a safer and more reliable drug preparation for the treatment of complex drug-resistant pathogenic bacterial skin or soft tissue infection.

The present invention relates to peptides, fusion proteins and compositions for inducing an immune response against bacteria. The invention also relates to the treatment or prevention of infections by sepsis-inducing bacteria, and to the treatment and prevention of pathological conditions caused by such bacteria. Such pathological conditions include sepsis, pneumonia, meningitis, endocarditis, enterocolitis, urinary tract infection, soft tissue infection, gastrointestinal tract infection, bloodstream infection, encephalitis, premature delivery and dead delivery.

The invention discloses a synergistic bactericidal composition which comprises the following components: 16 g / mL-2048 g / mL of cortex albiziae extract, 10 g / mL-20 g / mL of plant extract, 10 g / mL-20. The content of the macrolide antibiotics is 0.0625 g / mL to 4096 g / mL; the bacteria are staphylococcus aureus or methicillin-resistant staphylococcus aureus, and the macrolide antibiotics are erythromycin or azithromycin. The invention also discloses application of the synergistic bactericidal composition in preparation of medicines for treating skin and soft tissue infection. According to the composition provided by the invention, macrolide antibiotics, such as erythromycin and azithromycin, which only have a bacteriostatic effect traditionally can be converted into preparations which have definite bactericidal activity on staphylococcus aureus and drug-resistant strains thereof. After the cortex albiziae extract and the antibiotics are combined for use, an extremely strong synergistic effect is shown, and the concentrations required when the cortex albiziae extract and the antibiotics take effect independently can be greatly reduced.

The invention relates to an immunosuppressive bone and soft tissue infection diagnosis biomarker combination and application thereof, the biomarker combination is ARG1 and LCN2, and when the expression quantity of ARG1 and LCN2 is up-regulated, the bone and soft tissue infection immune microenvironment of a subject is in an inhibition state. Compared with the prior art, the built biomarker combination exceeds a traditional binary diagnosis mode for judging whether infection exists or not, whether the bone and soft tissue infection local immune microenvironment is in an inhibition state or not can be accurately evaluated, and whether bone and soft tissue infection local immunosuppressive cells MDSCs are abnormally increased or not can be prompted.

The invention relates to a composition for use in a method of treating a bacterial infection selected from a bacterial urinary tract infection, a bacterial respiratory tract infection, a bacterial soft tissue infection and a bacterial bone infection in a patient, the composition comprising ribose and the amino acids glycine, alanine and glutamine in aqueous solution, the method comprising orally administering the composition to the patient additionally treated with an antibiotic.